Stock HLUN B H. LUNDBECK A/S
Add to a list
To use this feature you must be a member
Log inSign up

H. Lundbeck A/S Stock

Equities

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 11:20:00 2024-06-11 am EDT 		5-day change 1st Jan Change
37.66 DKK +1.78% Intraday chart for H. Lundbeck A/S +2.73% +14.96%
Jun. 03 Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia CI
May. 15 H LUNDBECK : Q1 beat adds momentum to the recent share price rally Alphavalue

Financials

Sales 2024 * 21.1B 3.04B Sales 2025 * 22.21B 3.2B Capitalization 35.92B 5.18B
Net income 2024 * 3.08B 443M Net income 2025 * 3.46B 498M EV / Sales 2024 * 1.49 x
Net cash position 2024 * 4.47B 644M Net cash position 2025 * 8.04B 1.16B EV / Sales 2025 * 1.26 x
P/E ratio 2024 *
12.1 x
P/E ratio 2025 *
10.4 x
Employees 5,681
Yield 2024 *
2.42%
Yield 2025 *
2.78%
Free-Float 30.74%
More Fundamentals * Assessed data

Chart H. Lundbeck A/S

Dynamic Chart

Latest news about H. Lundbeck A/S

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia CI
H LUNDBECK : Q1 beat adds momentum to the recent share price rally Alphavalue
Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024 CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period Alphavalue
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024 CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia CI
H. Lundbeck A/S Announces Management Appointments CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023 CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug MT
More news

Latest transcript on H. Lundbeck A/S

Logo H. Lundbeck A/S
H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024
More transcripts

Analyst Recommendations on H. Lundbeck A/S

H LUNDBECK : Q1 beat adds momentum to the recent share price rally Alphavalue
H LUNDBECK : Lundbeck is well-poised to sail through the transition period Alphavalue
More recommendations

Press releases H. Lundbeck A/S

Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia AQ
Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024 AQ
Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck AQ
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD AQ
Lundbeck : Articles of Association PU
More press releases

Quotes and Performance

1 day+0.30%
1 week+1.42%
Current month-1.48%
1 month+5.75%
3 months+14.97%
6 months+15.25%
Current year+13.49%
More quotes

Highs and lows

1 week
36.54
Extreme 36.54
37.36
1 month
34.34
Extreme 34.34
38.72
Current year
31.62
Extreme 31.62
38.72
1 year
30.96
Extreme 30.96
39.82
3 years
23.30
Extreme 23.295
39.84
5 years
23.30
Extreme 23.295
39.84
10 years
23.30
Extreme 23.295
39.84
More quotes

ETFs positioned on H. Lundbeck A/S

Name Weight AuM 1st Jan change Investor Rating
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD ETF First Trust IPOX Europe Equity Opportunities ETF - Distributing - USD
0.25% 4 M€ +15.94%
SPDR MSCI WORLD SMALL CAP UCITS ETF - USD ETF SPDR MSCI World Small Cap UCITS ETF - USD
0.02% 775 M€ -.--% -
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.01% 10 M€ -3.35% -
More ETFs positioned on H. Lundbeck A/S

Quotes

Date Price Change Volume
24-06-11 37.66 +1.78% 1 410 021
24-06-10 37 +0.22% 288,289
24-06-07 36.92 +0.33% 371,465
24-06-06 36.8 +0.38% 355,533
24-06-04 36.66 -1.03% 384,535

Delayed Quote Nasdaq Copenhagen, June 11, 2024 at 06:04 am EDT

More quotes

Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Sector
Pharmaceuticals
Calendar
2024-08-20 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for H. Lundbeck A/S

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
37 DKK
Average target price
39.96 DKK
Spread / Average Target
+8.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
H. LUNDBECK A/S Stock H. Lundbeck A/S
+13.49% 5.17B
MCKESSON CORPORATION Stock McKesson Corporation
+27.71% 76.86B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.94% 24.07B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+6.60% 9.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+12.25% 8.67B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-24.34% 7.58B
GALENICA AG Stock Galenica AG
+2.20% 4.12B
EBOS GROUP LIMITED Stock EBOS Group Limited
-7.75% 3.87B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-1.36% 3.63B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+20.13% 3.58B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. HLUN B Stock